BioConnections
  • Home page
  • Antibiotic Resistance
  • CHROMagar
  • Coris RESIST
  • Coris BioConcept ICT
  • Gonogen
  • MICROBIOLOGICS
  • MICRONAUT Broth Microdilution
    • yeasts&moulds
  • Mycology
  • Rosco Neo-sensitabs
  • REAL saliva
  • Rosco Phenotyping
  • Sifin Antisera
  • About
  • contact
  • TAT fungalDiagnostics
  • MBLo Bruker Controls

Current Mycology Topics
UK Laboratories are unprepared - Can we improve TAT for fungal disease diagnostics? - Rapid Fungal Diagnostics - Antifungal Susceptibility Testing & AFS - Invasive Aspergillosis Key Publications - Pulmonary Aspergillosis Key Publications - Towards Antifungal Stewardship

UK Laboratories are unprepared
​In recent years there have been increasing reports of invasive fungal disease and the emergence of more intrinsically resistant species of pathogenic fungi, such as Candida auris. ESPAUR initiated an analysis of current practices in diagnosis and treatment of mycological infections. Key findings published the 2019 report ‘National mycology laboratory diagnostic capacity for invasive fungal diseases in 2017;
A report commented under ‘Highlights’
  • There is a need to improve the UK diagnostic capacity for invasive fungal diseases.
  • A minority of laboratories have local access to β-glucan and galactomannan testing
  • Susceptibility testing of Aspergillus is currently conducted by few laboratories
journal_of_inection_2019_sub-optimal.pdf
File Size: 193 kb
File Type: pdf
Download File

Can we improve TAT for fungal disease diagnostics?
​A second report, 'An investigation of antifungal stewardship programmes in England' included the following comments;
 'There is an urgent need to improve across many diagnostic areas including the timely accessibility of/to fungal biomarkers and susceptibility testing.'  
'Clinicians say: lack of diagnostic tests or long TAT’s of tests is a main issue when managing patients with suspected invasive fungal infections.'
​
an_investigation.pdf
File Size: 161 kb
File Type: pdf
Download File

Can we reduce empirically prescribed antifungal treatments?
The availability of rapid diagnostics and in-house EUCAST broth microdilution will help create an AFS programme.
​
 The Pharmaceutical Journal, July 2019, Vol 303, No 7927, online     


​
​
 NHS Antifungal Stewardship Implementation Pack
pss1-meds-optimisation-trigger-5-antifungal-stewardship-implementation-pack-v7.pdf
File Size: 593 kb
File Type: pdf
Download File

How Long is Too Long?  Fungal biomarker turn-around-time (TAT) and antifungal stewardship.
 A median turn-around time of 1-2 weeks significantly devalues the use of fungal biomarkers 
fungal_biomarker_turn-around-time__tat__and_antifungal_stewardship__how_long_is_too_long____aspergillus___aspergillosis_website.pdf
File Size: 207 kb
File Type: pdf
Download File


Fungal Disease Diagnostics from BioConnections

Picture
Picture
Picture
​LDBIO The National Aspergillosis Centre in Manchester, UK has tested their LFA device  for Aspergillus antibody  ​and found it to be accurate, identifying 91% of cases of Chronic Pulmonary Aspergillosis in 30min. 
​

 ERA Biology ​​A pioneer in products for invasive fungal disease diagnosis.  Products include Aspergillus galactomannan, Beta-D-Glucan,and Cryptococcal capsular polysaccharide in LFA, EIA & PCR formats. 
​

MICRONAUT ​Broth microdilution is the technique that should be used for antifungal susceptibility according to EUCAST. This product has been evaluated and is in use in leading UK hospitals.

Invasive Aspergillosis  KEY PUBLICATIONS
COVID-19 associated invasive aspergillosis: data from the UK National Mycology Reference Laboratory. From the discussion 'In addition to radiological imaging, serial  screening for CAPA (CoVID Associated Pulmonary Aspergillosis) in ICU patients with deteriorating respiratory function should include:  (i) regular (at least weekly) Aspergillus antigen testing of serum samples, (ii) regular (at least  weekly) BDG testing of serum samples , (iii) Aspergillus antigen testing of BAL fluids (where  available) or non -directed lavages/tracheal aspirates and (iv) Aspergillus PCR in conjunction  with conventional mycological examination (microscopy and culture) of respiratory  secretions if available. '
Invasive fungal disease occurs often in critically ill patients with COVID-19 on mechanical ventilation, according to a study published in Clinical Infectious Diseases.​​
A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU​ 
​
​​Confronting and mitigating the risk of COVID-19 Associated Pulmonary Aspergillosis (CAPA)  
mrl-2020-borman-jcm.02136-20.full.pdf
File Size: 888 kb
File Type: pdf
Download File

healio_article.pdf
File Size: 367 kb
File Type: pdf
Download File

strategy.pdf
File Size: 739 kb
File Type: pdf
Download File

capa.pdf
File Size: 819 kb
File Type: pdf
Download File


Pulmonary Aspergillosis  KEY PUBLICATIONS
Chronic Pulmonary Aspergillosis—Where Are We? and Where Are We Going?
'The use of Aspergillus IgG antibody as a diagnostic tool is far superior to the use of Aspergillus precipitins and should always be used as the gold standard ..to confirm infection.'
J. Fungi 2016, 2(2), 18; https://doi.org/10.3390/jof2020018​

    Evaluation of LDBio Aspergillus ICT Lateral Flow Assay for IgG and IgM Antibody Detection in Chronic Pulmonary Aspergillosis
Precis;

The LDBIO Aspergillus ICT IgG-IgM  immunochromatographic technology (ICT) test was compared with Aspergillus IgG titers in CPA patients, measured by ImmunoCAP-specific IgG assays (cutoff value, 40 mg of antigen-specific antibodies [mgA]/liter  For proven CPA patients versus controls, sensitivity and specificity for the LDBio Aspergillus ICT were 91.6% and 98.0%, respectively.  In contrast, the routinely used ImmunoCAP assay exhibited 80.5% sensitivity for the same cohort 
Of the 154 patients in our CPA case group, 108 had precipitins testing (for Aspergillus antibody) performed as part of routine diagnostics, with 57.4% sensitivity.


cpa—where_are_we__and_where_are_we_going_.pdf
File Size: 8942 kb
File Type: pdf
Download File

ldbio__cpa__journal_of_clinical_microbiology.pdf
File Size: 717 kb
File Type: pdf
Download File

Picture
CLICK FOR LDBIO PAGE
Evaluation of the LDBio Aspergillus ICT lateral flow assay for serodiagnosis of allergic bronchopulmonary aspergillosis.
Precis;

Early recognition and diagnosis of allergic bronchopulmonary aspergillosis (ABPA) is critical
to improve patient symptoms, and antifungal therapy may prevent or delay progression of
bronchiectasis and development of chronic pulmonary aspergillosis.

ABPA and control sera collected at the National Aspergillosis Centre (Manchester, UK) and/or from the Manchester Allergy, Respiratory and Thoracic Surgery research biobank were evaluated using the Aspergillus ICT assay. Results were read both visually and digitally (using a lateral flow reader). Serological Aspergillus-specific IgG and IgE, and total IgE titres were measured by ImmunoCAP.
. The test effectively distinguished between Aspergillus-sensitization complicating asthma and/or bronchiectasis, and underlying conditions. It is rapid (result in <30 minutes) and easy to perform, with simple result interpretation by visible inspection. Overall, the LDBio Aspergillus ICT exhibits excellent performance as a screening tool in the ABPA diagnostic pathway
Published: September 25, 2020 https://doi.org/10.1371/journal.pone.0238855​
manchestereval.pdf
File Size: 1095 kb
File Type: pdf
Download File

Picture
CLICK FOR LDBIO PAGE
Towards an Antifungal Stewardship Programme  KEY PUBLICATIONS
An investigation of antifungal stewardship programmes in England. ..Cost issues are the main driver for AFS, followed by clinical need. The availability of rapid diagnostics and clinical support could help increase AFS initiatives.  Availability of  rapid diagnostics  and clinical support would help create an AFS programme.
an_investigation.pdf
File Size: 161 kb
File Type: pdf
Download File

Utility of 1,3 β-d-Glucan Assay for Guidance in Antifungal Stewardship Programs for Oncologic Patients and Solid Organ Transplant Recipients.  'the determination of BDG in SOT recipients and oncological patients is a tool that can be used to stop empirical prescribed AF treatments or to confirm the diagnosis of IFI. This is a cost-effective strategy that safely improves the results of an ASP based on bedside advice in a tertiary care hospital.'
Antifungal Stewardship Implementation Pack  This pack provides information and guidance to support the local implementation of this Improving Value initiative.  A checklist included that can be used to check local readiness for implementation.
Comparative Evaluation of Micronaut-AM and CLSI broth microdilution method for antifungal susceptibility testing of Aspergillus species against four commonly used antifungals.
Ali Nuh, Newara Ramadan, Silke Schelenz, Darius Armstrong-James.   doi: https://doi.org/10.1101/811901​
b-d-glucan_afsp.pdf
File Size: 283 kb
File Type: pdf
Download File

pss1-meds-optimisation-trigger-5-antifungal-stewardship-implementation-pack-v7.pdf
File Size: 593 kb
File Type: pdf
Download File

comparative_evaluation_of_micronaut-am_and_clsi_broth.pdf
File Size: 267 kb
File Type: pdf
Download File



​RECOMMENDED FOR UPDATES
Picture
Picture

​​

Picture

    How can we help?

Submit
Picture
Brindley Court, Victoria Business Park
Knypersley ST8 7PP
T: 01782 516 010 
E: welcome@bioconnections.co.uk
iso Accreditation certificate
Picture
  • Home page
  • Antibiotic Resistance
  • CHROMagar
  • Coris RESIST
  • Coris BioConcept ICT
  • Gonogen
  • MICROBIOLOGICS
  • MICRONAUT Broth Microdilution
    • yeasts&moulds
  • Mycology
  • Rosco Neo-sensitabs
  • REAL saliva
  • Rosco Phenotyping
  • Sifin Antisera
  • About
  • contact
  • TAT fungalDiagnostics
  • MBLo Bruker Controls